ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data
Image
Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.
ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001
IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.